All AbMole products are for research use only, cannot be used for human consumption.
Bioymifi is able to promote cell death without the need for the Smac mimetic in T98G cells. At a 10 μM concentration, bioymifi induces processing of caspase-3 into smaller fragments. Caspase-8 and the related extrinsic apoptotic pathway are essential for bioymifi-induced cell death. Bioymifi induces DR5-dependent death pathways and is independent of TRAIL. Bioymifi binds the ECD of DR5 with a Kd of 1.2 μM but shows little binding affinity to the DR4 ECD. It has poor solubility in buffer solutions. Bioymifi promotes apoptosis by directly binding to and facilitating aggregation of DR5. When bioymifi reaches micromolar concentration, its capability to aggregate DR5 is strong enough to induce apoptosis in various cancer cells.
| Cell Experiment | |
|---|---|
| Cell lines | Human glioblastoma (T98G) cells |
| Preparation method | Dose-response curves of bioymifi and A2C2 in T98G cells are plotted as a function of A2C2 or bioymifi concentration. Human glioblastoma (T98G) cells are treated with various concentrations of A2C2 or bioymifi alone or in combination with 1 μM Smac mimetic (SM) for 48 h. The corresponding cell survival is normalized to the treatment without A2C2 or bioymifi. |
| Concentrations | 0, 0.3, 1, 3, 10, 30 μM |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | |
| Formulation | |
| Dosages | |
| Administration | |
| Molecular Weight | 494.32 |
| Formula | C22H12BrN3O4S |
| CAS Number | 1420071-30-2 |
| Solubility (25°C) | DMSO 10 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[1] Wang G Nat Chem Biol. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells.
| Related TNF Receptor Products |
|---|
| Ozekibart
Ozekibart is an anti-TNFRSF10B monoclonal antibody. |
| TAPI-0
TAPI-0 is a TACE (TNF-α converting enzyme; ADAM17) inhibitor with an IC50 of 100 nM. |
| Semapimod tetrahydrochloride
Semapimod tetrahydrochloride (CNI-1493), an inhibitor of proinflammatory cytokine production, can inhibit TNF-α, IL-1β, and IL-6. |
| BMS-566394
BMS-566394 is a potent, exceptionally selective inhibitor of TNF-α converting enzyme (TACE). |
| APVO603
APVO603 is a dual agonist bispecific antibody employing a novel mechanism of action to simultaneously target 4-1BB (CD137) and OX40 (CD134), both members of the TNF-receptor family. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
